Altimmune to Present at Key Healthcare Conferences Amid Pemvidutide Development
Event summary
- Altimmune to participate in four investor conferences from March 9–12, 2026, including fireside chats at Leerink, Citizens, and Barclays events.
- One-on-one meetings scheduled across all four conferences for targeted investor engagement.
- Pemvidutide remains the company’s lead candidate for MASH, AUD, and ALD treatments.
- Webcasts of fireside chats available via Altimmune’s website.
The big picture
Altimmune’s participation in these high-profile investor conferences underscores its push to engage with institutional investors amid a critical phase of pemvidutide’s development. The focus on one-on-one meetings suggests targeted outreach to gauge investor appetite for its lead candidate, particularly as the biopharmaceutical sector faces increasing scrutiny over clinical trial outcomes and funding efficiency.
What we're watching
- Clinical Progress
- How upcoming pemvidutide trial results may influence investor sentiment during these conferences.
- Market Positioning
- Whether Altimmune can differentiate pemvidutide in the competitive landscape of liver disease treatments.
- Funding Strategy
- The pace at which Altimmune secures additional capital to advance pemvidutide through late-stage trials.